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Abstract 33 
Objective: UtS are a group of uncommon tumors representing 1% of malignant neoplasms of 34 
the female genital tract, and 7% of sarcomas. The objective of this study was to evaluate the 35 
factors associated with the clinical behavior UtS.  36 
Methods: Information on 269 patients with advanced or metastatic first line UtS treated by 37 
chemotherapy was available in a database containing information on 3270 patients with 38 
advanced soft tissue sarcomas (STS) entered in EORTC-STBSG clinical trials between 1977 and 39 
2010. The chemotherapy was aggregated in 4 categories: anthracyclines alone, ifosfamide 40 
alone, the combination of doxorubicin and ifosfamide, and CYVADIC.  41 
Results: Among the 269 UtS pts, there were 231 deaths (median OS 10.4 months, 95% CI: 9.1-42 
11.9) and 257 progressions and/or deaths (median PFS 4.1 months, 95% CI: 3.5-4.9). 43 
Multivariate analyses reported PS (p < 0.001) only to be a statistically significant prognostic 44 
factor for OS in UtS; for PFS, LMS histology (p = 0.025) is associated with a better outcome. 45 
There was no relationship between the 4 groups of chemotherapy regimens and impact on 46 
clinical outcomes. Histological subtype was significantly correlated with response to 47 
chemotherapy (RR: LMS 19% vs other 33%, p = 0.026). Ifosfamide single agent yielded only 5% 48 
of RR.  49 
Conclusions: Clearly, UtS are very aggressive neoplasms with poor outcome when treated with 50 
chemotherapy consisting of anthracyclines with or without ifosfamide or cyclophosphamide. 51 
New strategies are urgently needed. 52 
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INTRODUCTION  58 
Soft tissue sarcomas (STS) are rare tumors, and globally account for less than 1% of all 59 
malignancies. Uterine sarcomas (UtS) are rare malignancies representing approximately 8–10% 60 
of all uterine malignancies (1;2). Compared with the more common uterine carcinomas, UtS are 61 
more aggressive and have typically a worse prognosis. Their histopathological classification was 62 
revised by the World Health Organization (WHO) in 2003 including leiomyosarcomas (LMS) 63 
(70%), low grade endometrial stromal sarcomas (20%) and undifferentiated or poorly 64 
differentiated endometrial sarcomas (6%). More unusual UtS subtypes, such as liposarcoma, 65 
rhabdomyosarcoma, angiosarcoma, PEComa, representing all together less than 5% of all UtS, 66 
have also been reported (1). 67 
Because of their rarity and heterogeneity, no consensus has yet emerged on prognostic factors 68 
for clinical outcome and treatment strategy. There are actually several papers attempting to 69 
address prognostic factors in uterine sarcoma subtypes more specifically for LMS at initial 70 
diagnosis (2). In metastatic phase, systemic treatment is the recommended approach for the 71 
majority of patients (3). However, as for other STS, patients with metastatic disease should be 72 
evaluated to determine whether resection of metastases may be appropriate (4). 73 
Systemic treatment options for advanced or metastatic disease have most frequently been 74 
evaluated in phase II trials dedicated to UtS, or retrospective series (5). For monotherapeutic 75 
regimens such as doxorubicin, gemcitabine, ifosfamide, or trabectedin, a response rate lower 76 
than 25% was observed (6). Response rates are slightly better (25 to 50%) for combinations 77 
such as doxorubicin plus ifosfamide, gemcitabine plus docetaxel, gemcitabine plus dacarbazine, 78 
and more recently doxorubicin plus trabectedin (6-11).  79 
  
   4 
The objective of this study was to perform an exploratory, retrospective analysis of differences 80 
in patient and disease characteristics as compared to other STS sub-types, and to evaluate 81 
factors associated with the clinical outcome of patients with advanced or metastatic UtS 82 
treated by first line chemotherapy, using pooled data of patients registered in EORTC-STBSG 83 
sarcoma trials from 1977 to 2010. 84 
 85 
PATIENTS AND METHODS 86 
Patients included in the analysis 87 
The pooled database contains information on 3238 eligible chemotherapy-naïve patients out of 88 
3460 treated in thirteen EORTC-STBSG advanced STS trials (see ST1). UtS patients only (269 pts) 89 
were considered for the prognostic factor analysis. 90 
End points of the analysis 91 
The end points were overall survival (OS), progression free survival (PFS) and response rate to 92 
chemotherapy (RR). OS was computed from the date of randomisation (in randomised trials) or 93 
the date of prospective registration (in nonrandomised trials) to the date of death. Patients 94 
reported to be alive at the time of last follow-up were censored. PFS was defined from the date 95 
of randomisation/prospective registration to the date of progression or death, whichever 96 
occurred first. Patients alive and progression-free at the last follow-up were censored. RR was 97 
evaluated in all trials using WHO response criteria (12) or RECIST (13).  98 
Covariates 99 
We considered general patient characteristics such as age and baseline performance status (PS, 100 
measured on the WHO scale except for two trials in which it was retrospectively converted 101 
from the Karnofsky scale), variables related to the disease history, histopathological grade (as 102 
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the histological grading system was not homogeneous defined among the different trials and 103 
because of change of definition over time, it was decided to separate the low histopathological 104 
grade (grade I) vs other grade (grade II and III) or missing) and histology (whereby, if available, 105 
the diagnosis by a panel of reference pathologists was preferred over the local assessment). 106 
Adenosarcoma and carcinosarcoma were not included in the different trials as stated in the 107 
inclusion or exclusion criteria.   108 
Other variables related to the history of sarcoma were prior surgery, prior radiotherapy, and 109 
extent of disease at time of the inclusion. Treatment was aggregated in 4 categories: 110 
anthracyclines alone (doxorubicin 75 mg/m², caelyx 50mg/m², epirubicin 75 mg/m², epirubicin 111 
3*50 mg/m², epirubicin 150 mg/m²), ifosfamide alone (ifosfamide 5 g/m², ifosfamide 3*3 g/m², 112 
ifosfamide 9 g/m² cont., ifosfamide 12 g/m²), the combination of doxorubicin and ifosfamide 113 
(doxorubicin 50mg/m² with ifosfamide 5 g/m², doxorubicin 75 mg/m² with ifosfamide 5 g/m², 114 
doxorubicin 75 mg/m² with ifosfamide 10 g/m²) and CYVADIC (Adriamycin, 50 mg/m2, 115 
Cyclophosphamide, 500 mg/m2, Vincristine, 1.5 mg/m2 and Dacarbazine, 750 mg/m2). 116 
Statistical methods 117 
Categorical variables were summarized by frequencies and percentages, continuous covariates 118 
by median, range and interquartile range (IQR). The variables were presented according to 119 
primary tumor site (UtS versus other) and compared using either chi-square tests (categorical 120 
variables) or Kruskal-Wallis tests (continuous variables). Survival data was estimated by the 121 
Kaplan–Meier method. 122 
To identify significant prognostic factors among the baseline covariates, first univariate log rank 123 
tests were performed for OS and PFS and univariate logistic regression analyses for RR. 124 
Secondly, all factors were included in multivariate Cox (for OS and PFS) and logistic (for RR) 125 
regression models. Important factors were identified by a backward selection procedure. The 126 
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substantial amount of missing data in the variables prior surgery and histopathological grade 127 
leads to a considerable loss of information for the multivariate analyses. In the case of surgery, 128 
excluding the missing information would result in the exclusion of the most recent trial of the 129 
database. We thus considered “missing data” for these two factors as a separate category in 130 
the models. The statistical significance was set at 0.05 for all analyses in this report.  131 
RESULTS 132 
Table 1 lists the 3238 patient characteristics considered in this analysis by tumor origin (269 UtS 133 
patients vs. 2969 patients with other primary tumors gathered as ‘other types’). In this patient 134 
population, the expert panel reviewed 68% of initial histological diagnoses and 31% were 135 
discordant (see SF1). The majority of cases which were reclassified were leiomyosarcomas (106 136 
or 16%), MFH (98 or 15%) and tumors which were considered unclassifiable after central review 137 
(91 or 14%); 28% of tumors were reclassified as miscellaneous, for which in the majority of 138 
cases no further information was available. In the specific case of the uterine sarcomas, 12 139 
were leiomyosarcomas; 9 of which were reclassified as part of the miscellaneous category. 140 
Patients with UtS have generally different characteristics compared to those with other sites of 141 
tumor origin: the median age of the uterine sarcoma patients at registration was 53 years 142 
which is 3 years older than the median age of other patients. The extent of disease involved the 143 
primary site in 37.5% of UtS patients, while in 46% of the other patients. Disease free interval 144 
between diagnosis and registration for first line metastatic chemotherapy did not differ from 145 
other STS and in the majority of patients did not surpass 18 months. Furthermore, UtS patients 146 
had more often metastases in the lungs (68.8% vs 54.8%) but less often in the liver (12.3% vs 147 
17.4%). The majority of UtS patients (70.6%) had a leiomyosarcoma and none had synovial 148 
sarcoma while among the other patients only 26.7% had a leiomyosarcoma and 10.1% had 149 
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synovial sarcoma. Table ST2 reports details of histology: 53 (20%) of UtS patients were classified 150 
as miscellaneous sarcoma (more details were unfortunately not available in the databases).  151 
As the analysis is based on patients treated over 30 years, the impact of time effect on 152 
diagnosis and on outcome was investigated. The Uts patients were divided in two groups: 208 153 
patients enrolled before 2000 and 61 after 2000. The majority of uterine sarcoma patients 154 
enrolled after 2000 had age between 50-60 (54.1%) and in contrast to the patients registered 155 
before 2000 none had PS 2 or greater (0 vs 10.1%).  Data for primary surgery are often missing 156 
for patients enrolled after 2000 because this was not collected in the most recent trial. There 157 
was no significant difference between the survival of patients enrolled after 2000 vs before 158 
(p=0.493). 159 
Survival data of UtS compared to other STS 160 
Among the UtS patients, there were 231 deaths (median OS 10.4 months, 95% CI: 9.1-11.9) and 161 
257 progressions and/or deaths (median PFS 4.1 months, 95% CI: 3.5-4.9). Figure 1A & 1B 162 
reported OS and PFS for UtS versus other STS patients. There was no significant difference 163 
between the two groups (log rank test OS p = 0.098, PFS p = 0.183).  164 
Prognostic factors for overall survival in UtS patients 165 
Results of the univariate analyses of prognostic factors for OS are shown in table 2. PS and 166 
histopathological grade were found to be significant at a 5% level (see SF2 A & B). No impact of 167 
types of chemotherapy regimens (chemotherapy regimens containing doxorubicin versus no) 168 
by histological subtype (LMS versus other) on survival was observed (see SF3 A). In the 169 
multivariate model, only PS remained significant. The backward selection and the fit of the 170 
multivariate model were found to be somewhat unstable due to the amount of missing 171 
information for histopathological grade and prior surgery. Note that the results observed for 172 
the category of “missing information” on prior surgery (outcome similar to the outcome of 173 
  
   8 
patients with “known” surgery) seems to suggest that, at least in this subgroup of patients, 174 
the majority of these patients are likely to have received some surgery.  175 
Prognostic factors for progression free survival in UtS patients 176 
Results of the univariate analyses of prognostic factors for PFS are shown in table 3. PS and 177 
histological subtype are significant factors. No impact of types of chemotherapy regimens 178 
(chemotherapy regimens containing doxorubicin versus no) by histological subtype (LMS versus 179 
other) on PFS was observed (see SF2 B). Also here, the subgroup of patients for whom the 180 
surgery status is unknown had a similar outcome as those with known surgery. 181 
The multivariate model included factors identified as significant from backward selection. 182 
Histology (other vs LMS: HR 0.72, 95% CI 0.54 – 0.96, p=0.025) was significant. For PFS also, the 183 
multivariate analyses was found to be unstable due to missing data in the covariates.  184 
Response to chemotherapy  185 
The analysis of response to chemotherapy identified 60 (22.3%) responders among UtS patients 186 
(Table 4), however no significant difference was observed between the RRs observed from the 187 
different treatments (p=0.056). Table 5 summarizes the results of the univariate analyses of 188 
potential prognostic factors. Again, only histology remained significant in multivariate analysis. 189 
No impact of the type of chemotherapy regimen (doxorubicin containing regimen versus no 190 
doxorubicin) by histology on RR was noted. 191 
 192 
DISCUSSION 193 
This is the first study comparing the outcome of patients with advanced UtS with those with 194 
other STS histological subtypes. UtS patients in this retrospective analysis had a median PFS of 195 
4.1 months and a median survival time of 10.4 months, with no difference compared to other 196 
STS. These survival data may be supportive to include UtS patients in randomized trials 197 
  
   9 
exploring new options in metastatic phase for all STS patients. The univariate and multivariate 198 
analyses for overall survival demonstrated a prognostic impact of PS. As for PFS, a better 199 
outcome was observed for uterine patients with different histology from LMS. Compared to a 200 
previously reported subgroup analysis of MPNST using the EORTC databases (14), there was no 201 
significant effect of treatment regimen observed neither for PFS nor OS. A multivariate logistic 202 
regression analysis of response to chemotherapy identified only histology as a significant factor. 203 
The RR using doxorubicin alone or in combination is relatively low (but not so different 204 
compared to other STS subtypes), compared to the RR with ifosfamide alone, which is really 205 
low. Therefore, it should be recommended to avoid ifosfamide alone for patients in situations 206 
where achieving response is of clinical relevance, e.g. to reduce symptoms or to improve 207 
surgical resectability. On the other hand, CYVADIC regimen using dacarbazine in combination 208 
(8;15) with other drugs provided the highest RR (35%) compared to others.  209 
The low RR reported for UtS patients included in these large randomized phase III trials (except 210 
3 non randomized) contrasted with the higher RR published or reported in non-randomized 211 
very selected phase II trials using doxorubicin plus or less other compounds such as trabectedin 212 
(17;18), gemcitabine and docetaxel (7), or gemcitabine and dacarbazine (11) (S3).  213 
Randomised trials are needed to confirm results from non-randomised phase II studies 214 
(specifically when using combination chemotherapy regimens vs monotherapy) before 215 
considering one rather than the other.  216 
Considering OS data of the current analysis and previously reported prospective randomized 217 
trials, single-agent doxorubicin is still considered the standard chemotherapy. The Cochrane 218 
review in 2006 concluded that combination regimens, compared with single-agent doxorubicin, 219 
produced only marginal increases at the expense of increased toxic effects, with no 220 
improvements in overall survival (19). Recent results of the EORTC 62012 trial in advanced STS 221 
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confirmed such analysis for all STS (20). Initial combination therapy may be considered 222 
appropriate only for those patients with good PS, no comorbidity and who would be expected 223 
to tolerate the increased toxicity, particularly if objective response is considered important for 224 
symptomatic improvement or patients with high grade undifferentiated sarcoma. 225 
The weakness of this study lies in its being a retrospective analysis using data from patients 226 
treated up to more than 30 years ago with only 68% reported histological review for initial 227 
diagnosis. In several of the (older) trials histology was reported using a limited level of detail 228 
(often at most 10-12 categories, including “miscellaneous” and “unclassifiable”). During this 229 
period the tumor histology classification has undergone several changes, with the most recent 230 
WHO classification released in 2013 containing a reclassification of MFH tumors. Nevertheless, 231 
fewer patients with uterine sarcoma were reclassified as compared to the general patient 232 
population considered in this study (14% versus 31%). This increases our confidence in the 233 
results of the analyses looking at the prognostic value of histology on the outcome of uterine 234 
sarcoma patients. 235 
Other possible prognostic factors that could not be studied as cofactors are: mitotic index, 236 
molecular classification, initial surgery quality (free margins or not) and initial FIGO stage (21). 237 
The apparent differences of RR between therapeutic regimens may be explained by selection 238 
bias and should be confirmed on the basis of randomized data.  239 
The benefit of chemotherapy for metastatic disease should be weighed against the possible 240 
side-effects. New drugs and drug combinations with promising targeted therapies, such as 241 
pazopanib (22), sorafenib & bevacizumab reported marginal effects, while cabozantinib and 242 
trabectedin are currently being studied in advanced STS including UtS (NCT 01979393, 243 
NCT02249702). The data extracted from EORTC databases greatly support that doxorubicin 244 
alone or in combination with ifosfamide could be the best control arm in first line treatment to 245 
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explore new combinations or treatment, such as gemcitabine-docetaxel or doxorubicin-246 
trabectedin, specifically in the field of LMS.  247 
The last question is how to evolve in future clinical trials dedicated to UtS? The options are to 248 
perform 1) either large (and thus most probably, global) phase III trials including all high grade 249 
UtS to evaluate the best chemotherapy regimen compared to standard chemotherapy (a 250 
doxorubicin based regimen), or 2) stratified clinical trials including all uterine subtypes (LMS, 251 
high grade undifferentiated sarcoma, high grade adenosarcoma with overgrowth) or 3) 252 
separate clinical trials asking several questions (one major endpoint and several secondary 253 
endpoints) but more dedicated to each subtypes.  Results of ongoing trials will hopefully help to 254 
address these burning questions in this group of patients with such an overt need for 255 
improvement in outcome.  256 
CONCLUSIONS  257 
This study reports the outcome of a really important series of UtS patients in first line 258 
treatment with advanced or metastatic disease within randomised trials. The results in term of 259 
PFS, OS and RR highlight the poor prognosis of this population, low RR to chemotherapy with 260 
doxorubicin alone or in combination with ifosfamide and the need to confirm results about RR, 261 
PFS or OS of published non-randomised phase II trials in selected population of patients. These 262 
results clearly show the urgent need for innovative new strategies including new compounds in 263 
this group of patients for whom OS is less than 10 months. 264 
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Figures and Tables 370 
 371 
Table 1: Patient, tumor and treatment characteristics of UtS patients compared to patients 372 
with tumors in other sites of origin (a = Kruskal-Wallis test; b = Chi-square test, IQR = 373 
Interquartile range). 374 
 375 
 
Tumor site 
Uterine sarcoma 
(N = 269) 
Other types (N = 
2969) 
Total (N = 
3238) p-Value 
N (%) N (%) N (%) 
Performance status 
 
0.299b 
PS 0 128 (47.6) 1251 (42.1) 1379 (42.6)  
PS 1 117 (43.5) 1350 (45.5) 1467 (45.3)  
PS 2+ 21 (7.8) 277 (9.3) 298 (9.2) 
 
Unknown 3 (1.1) 91 (3.1) 94 (2.9) 
 
Treatment 
 
0.015b 
Anthracyclins 119 (44.2) 1146 (38.6) 1265 (39.1)  
DOX+IFO 87 (32.3) 1040 (35.0) 1127 (34.8)  
CYVADIX 23 (8.6) 429 (14.4) 452 (14.0)  
IFO ALONE 40 (14.9) 354 (11.9) 394 (12.2)  
Histopathological grade  0.035b 
Low 12 (4.5) 262 (8.8) 274 (8.5) 
 
Intermediate/high 178 (66.2) 1810 (61.0) 1988 (61.4)  
Unknown 79 (29.4) 897 (30.2) 976 (30.1)  
Histology 
 
<0.001b 
Leiomyosarcoma 190 (70.6) 792 (26.7) 982 (30.3)  
Synovial sarcoma 0 (0.0) 300 (10.1) 300 (9.3) 
 
Other 69 (25.7) 1730 (58.3) 1799 (55.6)  
Unknown 10 (3.7) 147 (5.0) 157 (4.8) 
 
Prior surgery 
 
<0.001b 
No surgery 10 (3.7) 337 (11.4) 347 (10.7)  
Non optimal surgery 40 (14.9) 484 (16.3) 524 (16.2)  
Complete surgery 117 (43.5) 856 (28.8) 973 (30.0)  
Unknown 102 (37.9) 1292 (43.5) 1394 (43.1)  
Prior radiotherapy 
 
0.527b 
No 186 (69.1) 2104 (70.9) 2290 (70.7)  
Yes 81 (30.1) 839 (28.3) 920 (28.4)  
Unknown 2 (0.7) 26 (0.9) 28 (0.9) 
 
Extent of disease 
  
Primary 101 (37.5) 1366 (46.0) 1467 (45.3) <0.001b 
Liver metastases 33 (12.3) 518 (17.4) 551 (17.0) 0.022b 
Lung metastases 185 (68.8) 1626 (54.8) 1811 (55.9) <0.001b 
Bone metastases 22 (8.2) 308 (10.4) 330 (10.2) 0.148b 
Other metastases 105 (39.0) 1120 (37.7) 1225 (37.8) 0.782b 
Age at registration (years)   
 
<0.001a 
Median (IQR) 53 (47–59) 50 (39–59) 51 (40–59)  
Range 22–76 10–80.0 10–80 
 
N obs 262 2905 3167 
 
Time between initial diagnosis 
and registration (months) 
   0.673a 
Median (IQR) 6.8 (1.7–15.3) 6.2 (1.3–18.4) 6.3 (1.4–18.0) 
 
Range 0.0–199.5 0.0–346.5 0.0–346.5 
 
N obs 266 2766 3032 
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Table 2: Univariate analyses of potential prognostic factors for overall survival of UtS patients 378 
(a = These missing values were considered as a separate category to avoid a considerable loss 379 
of patient information from the analyses). 380 
 381 
 Covariates 
Patients 
(N) 
Observed 
Events (O) 
Hazard Ratio 
(95% CI) 
p-Value 
(logrank test) 
Performance status PS 0 128 102 1 <0.001 (df=2) 
 
PS 1 117 105 1.61 (1.22, 2.12)  
 
PS 2+ 21 21 3.16 (1.96, 5.09)  
 
Missing 3 
   
Prior Surgery No surgery 10 10 1 0.633 (df=3) 
 
Non optimal surgery 40 32 0.64 (0.31, 1.31)  
 
Complete surgery 117 99 0.66 (0.34,1.27)  
 
Missinga 102 90 0.69 (0.36, 1.33)  
Prior radiotherapy No 186 155 1 0. 782 
 
Yes 81 74 1.04 (0.79, 1.37)  
 
Missing 2 
   
Primary site involved No 145 124 1 0. 829 
 
Yes 101 86 0.97 (0.73, 1.28)  
 
Missing 23 
   
Histopathologicalgrade Low 12 8 1 0.040 (df=2) 
 
Intermediate/high 178 160 2.55 (1.19, 5.47)  
 
Missinga 79 63 2.27 (1.04, 4.98)  
Treatment Anthracyclins 119 104 1 0.945 (df=3) 
 
DOX+IFO 87 78 1.08 (0.80,1.45)  
 
CYVADIX 23 20 0.96 (0.59, 1.55)  
 
IFO ALONE 40 29 1.00 (0.66, 1.52)  
Age (cat) <40yrs. 26 20 1 0.101 (df=3) 
 
40–50yrs. 72 63 1.66 (0.99, 2.78)  
 
50–60yrs. 102 88 1.81 (1.10, 2.99)  
 
≥60yrs. 62 54 1.86 (1.10, 3.15)  
 
Missing 7 
   
Histology Leiomyosarcoma 190 166 1 0.111 
 
Other 69 56 0.78 (0.57,1.06)  
 
Missing 10 
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Table 3: Univariate analyses of potential prognostic factors for PFS in UtS patients (a = These 383 
missing values were considered as a separate category to avoid a considerable loss of patient 384 
information from the analyses). 385 
 386 
Covariates 
Patients 
(N) 
Observed 
Events (O) 
Hazard Ratio  
(95% CI) 
p-Value 
(logrank test) 
Performance status PS 0 128 118 1 0.038 (df=2) 
 
PS 1 117 115 1.23 (0.95,1.59)  
 
PS 2+ 21 21 1.76 (1.10, 2.80)  
 
Missing 3 
   
Prior Surgery No surgery 10 10 1 0.094 (df=3) 
 
Non optimal surgery 40 35 0.41 (0.20, 0.83)  
 
Complete surgery 117 113 0.49 (0.26, 0.95)  
 
Missinga 102 99 0.50 (0.26, 0.97)  
Prior radiotherapy No 186 176 1 0.912 
 
Yes 81 79 1.02 (0.78, 1.32)  
 
Missing 2 
   
Primary site involved No 145 139 1 0.759 
 
Yes 101 96 0.96 (0.74, 1.25)  
 
Missing 23 
   
HistopathologicalGrade* Low 12 11 1 0.066 (df=2) 
 
Intermediate/high 178 172 2.04 (1.11, 3.77)  
 
Missinga 79 74 1.92 (1.02, 3.63)  
Treatment Anthracyclins 119 112 1 0.303(df=3) 
 
DOX+IFO 87 84 1.18 (0.89, 1.56)  
 
CYVADIX 23 23 0.83 (0.53, 1.31)  
 
IFO ALONE 40 38 1.25 (0.86, 1.81)  
Age <40yrs. 26 21 1 0.070 (df=3) 
 
40–50yrs. 72 70 1.76 (1.07, 2.89)  
 
50–60yrs. 102 100 1.89 (1.17, 3.05)  
 
≥60yrs. 62 59 1.79 (1.08, 2.97)  
 
Missing 7 
   
Histology Leiomyosarcoma 190 185 1 0.024 
 
Other 69 63 0.72 (0.54, 0.96)  
 
Missing 10 
   
 387 
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Table 4: Response to chemotherapy regimen. 390 
 391 
 392 
 
Treatment 
Anthracyclins 
(N = 119) 
DOX + IFO 
(N = 87) 
CYVADIC 
(N = 23) 
IFO alone 
(N = 40) 
Total 
(N = 269) 
N (%) N (%) N (%) N (%) N (%) 
B
e
s
t 
o
v
e
ra
ll 
re
s
p
o
n
s
e
 
Complete response 3 (2.5) 2 (2.3) 3 (13.0) 0 (0.0) 8 (3.0) 
Partial response 26 (21.8) 19 (21.8) 5 (21.7) 2 (5.0) 52 (19.3) 
No change 51 (42.9) 29 (33.3) 7 (30.4) 15 (37.5) 102 (37.9) 
Progression 33 (27.7) 28 (32.2) 5 (21.7) 17 (42.5) 83 (30.9) 
Non evaluable 6 (5.0) 9 (10.3) 3 (13.0) 6 (15.0) 24 (8.9) 
  393 
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Table 5: Univariate analyses of potential prognostic factors for RR in UtS patients (a = These 399 
missing values were considered as a separate category to avoid a considerable loss of patient 400 
information from the analyses).   401 
 402 
 Covariates 
Response  
(N) 
Response 
rate (%) 
OR OR (95% CI) p-Value 
Performance status PS 0 32 25 1 1 0.479 (df=2) 
 
PS 1 22 18.8 0.69 (0.38, 1.28)  
 
PS 2+ 4 19.1 0.71 (0.22, 2.25)  
Missing 3 
     
Prior surgery No surgery 2 20 1 
 
0.849 (df=3) 
 
Non optimal 
surgery 
10 25 1.33 (0.24, 7.35)  
 
Complete surgery 28 23.9 1.26 (0.25, 6.27)  
 
Missinga 20 19.6 0.98 (0.19, 4.95)  
Prior radiotherapy No 44 23.7 1 
 
0.483 
 
Yes 16 19.8 0.79 (0.42, 1.51)  
 
Missing 2 
    
Primary site involved No 30 20.7 1 
 
0.452 
 
Yes 25 24.8 1.26 (0.69, 2.31)  
 
Missing 23 
    
Histopathological grade Low 3 25 1 
 
0.962 (df=2) 
 
Intermediate/high 39 21.9 0.84 (0.22, 3.26)  
 
Missinga 18 22.8 0.89 (0.22, 3.62)  
Treatment Anthracyclins 29 24.4 1 
 
0.056 (df=3) 
 
DOX+IFO 21 24.1 0.99 (0.52, 1.88)  
 
CYVADIX 8 34.8 1.66 (0.64, 4.3)  
 
IFO ALONE 2 5 0.16 (0.04, 0.72)  
Age <40yrs. 8 30.8 1 
 
0.588 (df=3) 
 
40–50yrs. 17 23.6 0.7 (0.26, 1.88)  
 
50–60yrs. 19 18.6 0.52 (0.20, 1.36)  
 
≥60yrs. 14 22.6 0.66 (0.24, 1.83)  
 
Missing 7 
    
Histology Leiomyosarcoma 36 19 1 
 
0.016 
 
Other 23 33.3 2.14 (1.15, 3.97)  
 
Missing 10 
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Figure 1: Overall survival (A) and progression-free survival (B) by tumor origin. 408 
 409 
 410 
 411 
